洞察德克斯梅托米丁的心脏保护作用和机制
Leyu Jiang1, Wei Xiong2, Yuqiao Yang1
1Department of Anesthesiology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Cardiovascular drugs and therapy
|June 13, 2024
概括
德克斯梅德托米丁通过调节细胞死亡,炎症和线粒体功能来表现出心脏保护作用. 本综述探讨了其治疗心血管疾病的潜在机制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 心血管疾病是全球主要的死亡原因.
- 德克斯梅德托米丁是一种选择性α2上腺素受体激动剂,具有镇静剂,止痛剂和交感解药性质.
- 新出现的证据表明,德克斯梅德托米丁可能会对心脏损伤提供保护.
研究的目的:
- 综合审查和阐明德克斯梅德托米丁的心脏保护机制.
- 探索德克斯梅德托米丁在治疗心脏损伤方面的潜在临床应用.
- 巩固目前对德克斯梅德托米丁在心血管健康中的作用的理解.
主要方法:
- 对调查德克斯梅德托米丁和心脏损伤的研究进行系统文献综述.
- 对德克斯梅托米丁对心脏的药理作用的临床前和临床数据的分析.
- 综合了与分子和生理机制有关的发现.
主要成果:
- 德克斯梅德米丁通过多种途径减轻心脏损伤.
- 关键机制包括调节编程细胞死亡,自和纤维化.
- 它还可以缓解炎症反应,内皮功能障碍和微循环问题.
结论:
- 德克斯梅德托米丁通过多种机制表现出有希望的心脏保护作用.
- 它改善了线粒体功能,血液动力学,并减少了心律失常.
- 德克斯梅德托米丁在心血管疾病治疗中具有显著的临床使用潜力.
相关概念视频
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Skeletal Muscle Relaxants: Adverse Effects
354
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
354
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823
Parenteral Anesthetics: Overview
118
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
118
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420


